美国住院COVID-19或MIS-C儿童及青少年的神经系统受累情况
该病例系列纳入美国61家医院2020年3月15日至12月15日住院的1695例<21岁SARS-CoV-2阳性患者,其中365例(22%)存在神经系统受累,多数为短暂症状;43例(12%)发生危及生命的神经系统病变,出院时17例(40%)遗留新发神经功能缺损,11例(26%)死亡。
要点
- 住院COVID-19或MIS-C儿童中22%有神经系统受累,多为短暂症状。
- 12%的神经系统受累者发生危及生命的病变,包括脑病、卒中、中枢感染/脱髓鞘等。
- 危及生命者中性粒细胞/淋巴细胞比值中位数12.2 vs 4.4,D-二聚体>3 μg/mL比例49% vs 22%。
核心结论
- 住院COVID-19或MIS-C儿童和青少年中神经系统受累常见,但多为短暂症状。
- 与COVID-19相关的危及生命和致死性神经系统病变不常见但确实发生。
- 对长期神经发育结局的影响尚不明确。
研究设计与样本
- 研究为病例系列,纳入2020年3月15日至12月15日美国61家医院住院的<21岁SARS-CoV-2检测阳性患者。
- 共1695例患者,其中616例(36%)符合儿童多系统炎症综合征(MIS-C)标准。
- 神经系统受累定义为就诊或住院期间出现急性神经系统体征、症状或疾病。
主要发现
- 1695例中365例(22%)来自52个中心有记录的神经系统受累。
- 神经系统受累者中322例(88%)为短暂症状且存活,43例(12%)发生危及生命的病变。
- 危及生命病变包括严重脑病15例(其中5例伴压部病变)、卒中12例、中枢神经系统感染/脱髓鞘8例、吉兰-巴雷综合征/变异型4例、急性暴发性脑水肿4例。
- 43例危及生命者中17例存活者(40%)出院时存在新发神经功能缺损,11例(26%)死亡。
- 危及生命组中性粒细胞/淋巴细胞比值中位数12.2 vs 4.4,D-二聚体>3 μg/mL纤维蛋白原当量单位报告频率49% vs 22%。
临床怎么用
- 对住院COVID-19或MIS-C儿童应警惕神经系统受累,多数为短暂症状但需识别危及生命病变。
- 中性粒细胞/淋巴细胞比值升高和D-二聚体>3 μg/mL可能提示危及生命的神经系统病变风险。
局限性
- 长期神经发育结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Coronavirus disease 2019 (COVID-19) affects the nervous system in adult patients. The spectrum of neurologic involvement in children and adolescents is unclear. OBJECTIVE: To understand the range and severity of neurologic involvement among children and adolescents associated with COVID-19. SETTING, DESIGN, AND PARTICIPANTS: Case series of patients (age <21 years) hospitalized between March 15, 2020, and December 15, 2020, with positive severe acute respiratory syndrome coronavirus 2 test result (reverse transcriptase-polymerase chain reaction and/or antibody) at 61 US hospitals in the Overcoming COVID-19 public health registry, including 616 (36%) meeting criteria for multisystem inflammatory syndrome in children. Patients with neurologic involvement had acute neurologic signs, symptoms, or diseases on presentation or during hospitalization. Life-threatening involvement was adjudicated by experts based on clinical and/or neuroradiologic features. EXPOSURES: Severe acute respiratory syndrome coronavirus 2. MAIN OUTCOMES AND MEASURES: Type and severity of neurologic involvement, laboratory and imaging data, and outcomes (death or survival with new neurologic deficits) at hospital discharge. RESULTS: Of 1695 patients (909 [54%] male; median [interquartile range] age, 9.1 [2.4-15.3] years), 365 (22%) from 52 sites had documented neurologic involvement. Patients with neurologic involvement were more likely to have underlying neurologic disorders (81 of 365 [22%]) compared with those without (113 of 1330 [8%]), but a similar number were previously healthy (195 [53%] vs 723 [54%]) and met criteria for multisystem inflammatory syndrome in children (126 [35%] vs 490 [37%]). Among those with neurologic involvement, 322 (88%) had transient symptoms and survived, and 43 (12%) developed life-threatening conditions clinically adjudicated to be associated with COVID-19, including severe encephalopathy (n = 15; 5 with splenial lesions), stroke (n = 12), central nervous system infection/demyelination (n = 8), Guillain-Barré syndrome/variants (n = 4), and acute fulminant cerebral edema (n = 4). Compared with those without life-threatening conditions (n = 322), those with life-threatening neurologic conditions had higher neutrophil-to-lymphocyte ratios (median, 12.2 vs 4.4) and higher reported frequency of D-dimer greater than 3 μg/mL fibrinogen equivalent units (21 [49%] vs 72 [22%]). Of 43 patients who developed COVID-19-related life-threatening neurologic involvement, 17 survivors (40%) had new neurologic deficits at hospital discharge, and 11 patients (26%) died. CONCLUSIONS AND RELEVANCE: In this study, many children and adolescents hospitalized for COVID-19 or multisystem inflammatory syndrome in children had neurologic involvement, mostly transient symptoms. A range of life-threatening and fatal neurologic conditions associated with COVID-19 infrequently occurred. Effects on long-term neurodevelopmental outcomes are unknown.
引用
- LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021. PMID: 33666649. doi:10.1001/jamaneurol.2021.0504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。